SCHEMBL4274255

SCHEMBL4274255

CC(C)(C)OC(=O)NCCCN1CCC(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 12/20 0.61
RAD52 P43351 3/20 0.57
LMNA P02545 6/20 0.56
MAPT P10636 6/20 0.56
SMN1; SMN2 Q16637 5/20 0.56
CYP3A4 P08684 4/20 0.56
MAPK1 P28482 4/20 0.56
TP53 P04637 3/20 0.56
CYP1A2 P05177 3/20 0.56
HTR1A P08908 3/20 0.56
CYP2D6 P10635 3/20 0.56
CHRM1 P11229 3/20 0.56
DRD2 P14416 3/20 0.56
ADRA2B P18089 3/20 0.56
ADRA2C P18825 3/20 0.56
CHRM3 P20309 3/20 0.56
SLC6A2 P23975 3/20 0.56
HTR2A P28223 3/20 0.56
HTR2C P28335 3/20 0.56
SLC6A4 P31645 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30057046 0.91 FPR2 (0.68) FPR2RAD52LMNAMAPTSMN1; SMN2
SCHEMBL26000676 0.91 FPR2 (0.68) FPR2RAD52LMNAMAPTSMN1; SMN2
SCHEMBL4275410 0.89 RAD52 (0.51) FPR2RAD52LMNAMAPTSMN1; SMN2
SCHEMBL560221 0.89 KIF11 (0.68) FPR2RAD52LMNAMAPTSMN1; SMN2
SCHEMBL560237 0.89 FPR2 (0.67) FPR2RAD52LMNAMAPTSMN1; SMN2
SCHEMBL4271320 0.87 FPR2 (0.62) FPR2RAD52LMNAMAPTSMN1; SMN2
SCHEMBL4284895 0.86 FPR2 (0.64) FPR2RAD52LMNAMAPTSMN1; SMN2
SCHEMBL10168005 0.85 FPR2 (0.64) FPR2RAD52LMNAMAPTSMN1; SMN2
SCHEMBL4278875 0.85 FPR2 (0.60) FPR2RAD52LMNAMAPTSMN1; SMN2
SCHEMBL560706 0.85 FPR2 (0.58) FPR2RAD52LMNAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275557-A1 Novel Composition for Treatment of Diseases Related to Activated Lymphocytes IMMUNE CONTROL, INC. (US) 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275557-A1 Novel Composition for Treatment of Diseases Related to Activated Lymphocytes TPH1, HTR5A, HTR6 FPR2 43/4885RAD52 3118/4885LMNA 1507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.